ExpreS2ion Biotech Holding AB
STO:EXPRS2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ExpreS2ion Biotech Holding AB
Depreciation & Amortization
ExpreS2ion Biotech Holding AB
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Depreciation & Amortization
-kr1.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Depreciation & Amortization
-kr253m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Depreciation & Amortization
-kr3.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-26%
|
|
|
BioArctic AB
STO:BIOA B
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Depreciation & Amortization?
Depreciation & Amortization
-1.5m
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Depreciation & Amortization amounts to -1.5m SEK.
What is ExpreS2ion Biotech Holding AB's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
13%
Over the last year, the Depreciation & Amortization growth was 11%. The average annual Depreciation & Amortization growth rates for ExpreS2ion Biotech Holding AB have been -6% over the past three years , 13% over the past five years .
